NOUVELLE UTILISATION D'UN DÉRIVÉ DE CHROMONE EN TANT QUE COMPOSITION PHARMACEUTIQUE POUR PRÉVENIR ET TRAITER UNE FIBROSE AU MOYEN D'UNE ACTIVITÉ INHIBITRICE DE TRANSITION ÉPITHÉLIO-MÉSENCHYMATEUSE DE CELUI-CI
This invention relates to a new use of a chromone derivative as a pharmaceutical composition for the prevention and treatment of fibrosis using EMT inhibitory activity and, particularly, to the novel use of a chromone derivative as an agent for the prevention and treatment of fibrosis using the activity of the chromone derivative, which has been newly found to inhibit EMT. The pharmaceutical composition of the invention contains the chromone derivative of Chemical Formula 1 as an active ingredient, thus effectively inhibiting the activation of EMT to thereby enable the effective suppression of fibrosis of an organ or tissue due to the activation of EMT. In particular, cells that have already undergone fibrosis can be restored to their original normal condition, thus enabling the treatment of the middle or late stage of fibrosis, in addition to the prevention of fibrosis or initial response thereto.
